Med is a flagship clinical and translational research monthly journal published by Cell Press, the global publisher of trusted and authoritative science journals including Cell, Chem, and Joule. Our mission is to accelerate translation of bench research to the clinic by providing a communication forum for the exchange of knowledge, fresh ideas, and thought-leadership among translational researchers, clinicians, and Biotech and Pharma scientists as well as other medical research stakeholders. Our goal is to sustainably and ethically improve health globally. Med publishes rigorously vetted original research and state-of-the-art Review and Perspective articles across the translational and clinical continuum. Our translational research articles are deeply rooted in understanding disease mechanisms, with demonstrable functional impact and broad transformative insights. Our clinical studies cover case reports, first-in-human studies, and large-scale clinical trials, including phase IV, which have the potential to change the course of medical research and improve clinical practice. We are interested in research with likely immediate impact on clinical therapy. These include clinical studies, translational research papers addressing disease mechanism and/or therapies, biotechnology and engineering advances with important clinical impact, and resources (such as informational databases) of broad medical utility. Topics of interest for the journal include but are not limited to: Aging and health-span interventions: sarcopenia; senescence and senolytic treatments; dietary interventions; hormonal disorders. Biomedical engineering - new device optimization and diagnostic tools. Cancer: immuno-oncology; tumor evolution and cancer genetics; surgery and therapeutic modalities. Cardiovascular and metabolic disease: heart disease; diabetes; obesity; NAFLD/NASH. Genetics and cell-based therapies: medical genomics; CRISPR-based; RNAi; stem cells; organoids; transplantation. Health economics and public policy: global challenges; health access; public health interventions; clinical practices. Human microbiome: mechanistic studies of the human microbiomes impact on disease. Immunology: allergy and inflammation; autoimmunity; innate immunity; graft-versus host disease; vaccinology. Infectious diseases: HIV/AIDS; SARS; ebola; other bacterial, viral, fungal, or parasitic infections; infectious diseases epidemiology; antimicrobials and resistance. Neurology: Alzheimers disease; dementia; cognitive dysfunctions; brain-vascular dysfunction; Parkinsons and movement disorders; amyotrophic lateral sclerosis; depression; neuroengineering therapies.
Scope
Publisher
Impact factor
12.80
Open access
Yes
Open peer review
No
ARRIVE guidelines
Not required